Fate Therapeutics
FATE
132 hedge funds and large institutions have $76.3M invested in Fate Therapeutics in 2025 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 42 closing their positions.
967% more call options, than puts
Call options by funds: $64K | Put options by funds: $6K
3% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 40
5.01% less ownership
Funds ownership: 89.29% → 84.28% (-5%)
17% less funds holding
Funds holding: 159 → 132 (-27)
54% less capital invested
Capital invested by funds: $166M → $76.3M (-$90.1M)
60% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$9.55M |
| 2 |
JP Morgan Chase
New York
|
+$2.12M |
| 3 |
Citigroup
New York
|
+$1.42M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.23M |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$7.99M |
| 2 |
DM
Deerfield Management
New York
|
-$5.87M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.03M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$2.28M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.35M |
FATE Hedge Fund Activity: Q1 2025 in Review
132 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2025, worth a combined $76.3M — down 54% from $166M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of FATE and 17 opened new positions — a net loss of 25 holders — while 40 trimmed existing stakes and 41 added.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $9.55M. The largest seller was Bellevue Group, exiting entirely with an estimated $7.99M sold.
- 132 institutional investors held Fate Therapeutics (FATE) as of Q1 2025, down from 159 in Q4 2024.
- Funds reported $76.3M of Fate Therapeutics stock for Q1 2025, down 54% quarter-over-quarter.
- 17 funds opened new Fate Therapeutics positions in Q1 2025 and 42 closed out, a net change of -25 holders.
- The largest Fate Therapeutics buyer in Q1 2025 was Schonfeld Strategic Advisors, an estimated $9.55M added.
- The largest Fate Therapeutics seller in Q1 2025 was Bellevue Group, an estimated $7.99M sold.
Based on aggregated 13F filings for Q1 2025.